Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Hyaluronidase (ovine) | Hyaluronidase (ovine) can cause an increase in the absorption of Butanilicaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase (human recombinant) | Hyaluronidase (human recombinant) can cause an increase in the absorption of Butanilicaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase | Hyaluronidase can cause an increase in the absorption of Butanilicaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Technetium Tc-99m tilmanocept | Butanilicaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Butanilicaine is combined with Chloroprocaine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Butanilicaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Ropivacaine is combined with Butanilicaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Butanilicaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Butanilicaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Dyclonine is combined with Butanilicaine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Procaine is combined with Butanilicaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Prilocaine is combined with Butanilicaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Butanilicaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Butanilicaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Oxybuprocaine is combined with Butanilicaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cocaine is combined with Butanilicaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Mepivacaine is combined with Butanilicaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Levobupivacaine is combined with Butanilicaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Diphenhydramine is combined with Butanilicaine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Benzocaine is combined with Butanilicaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Phenol is combined with Butanilicaine. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Tetrodotoxin is combined with Butanilicaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Benzyl alcohol is combined with Butanilicaine. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Capsaicin is combined with Butanilicaine. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Etidocaine is combined with Butanilicaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Articaine is combined with Butanilicaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Tetracaine is combined with Butanilicaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Propoxycaine is combined with Butanilicaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Pramocaine is combined with Butanilicaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Butamben is combined with Butanilicaine. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Butacaine is combined with Butanilicaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Oxetacaine is combined with Butanilicaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Butanilicaine is combined with Ethyl chloride. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Butanilicaine is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Butanilicaine is combined with Quinisocaine. |
| Cetuximab | The risk or severity of methemoglobinemia can be increased when Cetuximab is combined with Butanilicaine. |
| Denileukin diftitox | The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Butanilicaine. |
| Leuprolide | The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Butanilicaine. |
| Peginterferon alfa-2a | The risk or severity of methemoglobinemia can be increased when Peginterferon alfa-2a is combined with Butanilicaine. |
| Goserelin | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Butanilicaine. |
| Asparaginase Escherichia coli | The risk or severity of methemoglobinemia can be increased when Asparaginase Escherichia coli is combined with Butanilicaine. |
| Interferon alfa-2a | The risk or severity of methemoglobinemia can be increased when Interferon alfa-2a is combined with Butanilicaine. |
| Aldesleukin | The risk or severity of methemoglobinemia can be increased when Aldesleukin is combined with Butanilicaine. |
| Gemtuzumab ozogamicin | The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Butanilicaine. |
| Pegaspargase | The risk or severity of methemoglobinemia can be increased when Pegaspargase is combined with Butanilicaine. |
| Trastuzumab | The risk or severity of methemoglobinemia can be increased when Trastuzumab is combined with Butanilicaine. |
| Rituximab | The risk or severity of methemoglobinemia can be increased when Rituximab is combined with Butanilicaine. |
| Tositumomab | The risk or severity of methemoglobinemia can be increased when Tositumomab is combined with Butanilicaine. |
| Alemtuzumab | The risk or severity of methemoglobinemia can be increased when Alemtuzumab is combined with Butanilicaine. |
| Octreotide | The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Butanilicaine. |
| Interferon alfa-2b | The risk or severity of methemoglobinemia can be increased when Interferon alfa-2b is combined with Butanilicaine. |
| Bevacizumab | The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Butanilicaine. |
| Masoprocol | The risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Butanilicaine. |
| Bortezomib | The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Butanilicaine. |
| Pipobroman | The risk or severity of methemoglobinemia can be increased when Pipobroman is combined with Butanilicaine. |
| Cladribine | The risk or severity of methemoglobinemia can be increased when Cladribine is combined with Butanilicaine. |
| Cabergoline | The risk or severity of methemoglobinemia can be increased when Cabergoline is combined with Butanilicaine. |
| Anagrelide | The risk or severity of methemoglobinemia can be increased when Anagrelide is combined with Butanilicaine. |
| Carmustine | The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Butanilicaine. |
| Chlorotrianisene | The risk or severity of methemoglobinemia can be increased when Chlorotrianisene is combined with Butanilicaine. |
| Amsacrine | The risk or severity of methemoglobinemia can be increased when Amsacrine is combined with Butanilicaine. |
| Pamidronic acid | The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Butanilicaine. |
| Bleomycin | The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Butanilicaine. |
| Chlorambucil | The risk or severity of methemoglobinemia can be increased when Chlorambucil is combined with Butanilicaine. |
| Raltitrexed | The risk or severity of methemoglobinemia can be increased when Raltitrexed is combined with Butanilicaine. |
| Mitomycin | The risk or severity of methemoglobinemia can be increased when Mitomycin is combined with Butanilicaine. |
| Bexarotene | The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Butanilicaine. |
| Vindesine | The risk or severity of methemoglobinemia can be increased when Vindesine is combined with Butanilicaine. |
| Valproic acid | The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Butanilicaine. |
| Gefitinib | The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Butanilicaine. |
| Floxuridine | The risk or severity of methemoglobinemia can be increased when Floxuridine is combined with Butanilicaine. |
| Megestrol acetate | The risk or severity of methemoglobinemia can be increased when Megestrol acetate is combined with Butanilicaine. |
| Tioguanine | The risk or severity of methemoglobinemia can be increased when Tioguanine is combined with Butanilicaine. |
| Aminoglutethimide | The risk or severity of methemoglobinemia can be increased when Aminoglutethimide is combined with Butanilicaine. |
| Vinorelbine | The risk or severity of methemoglobinemia can be increased when Vinorelbine is combined with Butanilicaine. |
| Valrubicin | The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Butanilicaine. |
| Sorafenib | The risk or severity of methemoglobinemia can be increased when Sorafenib is combined with Butanilicaine. |
| Streptozocin | The risk or severity of methemoglobinemia can be increased when Streptozocin is combined with Butanilicaine. |
| Trifluridine | The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Butanilicaine. |
| Gemcitabine | The risk or severity of methemoglobinemia can be increased when Gemcitabine is combined with Butanilicaine. |
| Teniposide | The risk or severity of methemoglobinemia can be increased when Teniposide is combined with Butanilicaine. |
| Epirubicin | The risk or severity of methemoglobinemia can be increased when Epirubicin is combined with Butanilicaine. |
| Lenalidomide | The risk or severity of methemoglobinemia can be increased when Lenalidomide is combined with Butanilicaine. |
| Altretamine | The risk or severity of methemoglobinemia can be increased when Altretamine is combined with Butanilicaine. |
| Flutamide | The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Butanilicaine. |
| Cisplatin | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Butanilicaine. |
| Alitretinoin | The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Butanilicaine. |
| Oxaliplatin | The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Butanilicaine. |
| Erlotinib | The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Butanilicaine. |
| Cyclophosphamide | The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Butanilicaine. |
| Toremifene | The risk or severity of methemoglobinemia can be increased when Toremifene is combined with Butanilicaine. |
| Vincristine | The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Butanilicaine. |
| Fluorouracil | The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Butanilicaine. |
| Pentostatin | The risk or severity of methemoglobinemia can be increased when Pentostatin is combined with Butanilicaine. |
| Methotrexate | The risk or severity of methemoglobinemia can be increased when Methotrexate is combined with Butanilicaine. |
| Vinblastine | The risk or severity of methemoglobinemia can be increased when Vinblastine is combined with Butanilicaine. |
| Medroxyprogesterone acetate | The risk or severity of methemoglobinemia can be increased when Medroxyprogesterone acetate is combined with Butanilicaine. |
| Imatinib | The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Butanilicaine. |
| Clofarabine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Butanilicaine. |
| Prednisone | The risk or severity of methemoglobinemia can be increased when Prednisone is combined with Butanilicaine. |